1996
DOI: 10.1111/j.1600-0773.1996.tb00172.x
|View full text |Cite
|
Sign up to set email alerts
|

The Use of β2‐Adrenoceptor Agonists in the Treatment of Bronchial Asthma

Abstract: All guidelines recommend short-acting inhaled beta 2-adrenoceptor agonists as the first-line drugs in acute asthma attacks and inhaled corticosteroids as the drugs of choice when regular daily treatment is needed. Short-acting inhaled beta 2-adrenoceptor agonists are not effective in reducing nocturnal awakenings because of their short duration of action. In addition there has been an intense debate about the regular use of these drugs. This debate is reviewed. They should only be used on "as needed basis". Th… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
9
0

Year Published

1999
1999
2015
2015

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 15 publications
(9 citation statements)
references
References 66 publications
0
9
0
Order By: Relevance
“…Like ICS, LABAs have also been associated with class‐related PD effects, although these are usually greatest with oral or parenteral LABAs . LABA‐related side effects including muscle tremor, decreases in blood potassium levels and cardiovascular effects, such as QTc prolongation, increased heart rate, and palpitations, have been seen following administration of some LABAs in patients with asthma or COPD . In clinical studies, vilanterol, at doses of 100 mcg, did not produce clinically significant beta‐agonist systemic effects .…”
Section: Discussionmentioning
confidence: 99%
“…Like ICS, LABAs have also been associated with class‐related PD effects, although these are usually greatest with oral or parenteral LABAs . LABA‐related side effects including muscle tremor, decreases in blood potassium levels and cardiovascular effects, such as QTc prolongation, increased heart rate, and palpitations, have been seen following administration of some LABAs in patients with asthma or COPD . In clinical studies, vilanterol, at doses of 100 mcg, did not produce clinically significant beta‐agonist systemic effects .…”
Section: Discussionmentioning
confidence: 99%
“…The samples were allowed to dry at room temperature in the dark for at least 4 h and No. 13 C (δ C ) 1 H(δ H ) a …”
Section: High-performance Liquid Chromatographymentioning
confidence: 99%
“…Salmeterol xinafoate as LABA with a 12-h duration of action showed positive experience in asthma [10], providing improvements in bronchodilator efficacy and patient outcomes compared with short-acting β-agonist (SABA), which have duration of action of only 4-6 h [11]. Salmeterol is usually prescribed only for severe persistent asthma following previous treatment with SABA, such as salbutamol and is prescribed concurrently with an inhaled corticosteroid (ICS), such as fluticasone [12,13]. The combination of the LABA and the ICS has been shown to have superior efficacy to either component given separately [14], a higher dose of ICS alone [15][16][17][18], or a combination of ICS and a leukotriene antagonist [19,20] or theophylline [21].…”
Section: Uses and Applicationsmentioning
confidence: 99%
“…83 Bronchodilators, such as the inhaled short-acting b 2 -agonists salbutamol (200 or 400 mg) and terbutaline (0.5 mg), are now regarded as symptom-relieving drugs to be given on an 'asneeded' basis. 84 This change in usage, from a regular four-times daily regimen (which, it was thought, would 'keep the airways open') to use only as needed, was catalysed by a study showing that the regular use of the potent short-acting b 2agonist fenoterol resulted in a significant deterioration of asthma control. 85 This deterioration was accompanied by a decline in lung function and increased airway responsiveness, 86 as well as more exacerbations, [85][86][87] despite concurrent use of ICS.…”
Section: Current Use Of B 2 -Agonists Regular Use and As-needed Usementioning
confidence: 99%